Sintaho Pharmaceutical

Executive Summary

Sintaho Pharmaceutical is a clinical-stage Chinese biotech focused on oncology and immunology, with a pipeline of novel therapeutics targeting the tumor microenvironment and immune response. The company is currently advancing its lead candidate through Phase 2 trials, leveraging its proprietary drug discovery platform. While specific financial and pipeline details remain undisclosed, the company's expertise in targeted therapies positions it to address significant unmet medical needs in cancer care. With a strong focus on innovation and a growing presence in Shanghai, Sintaho is poised to generate key clinical data over the next 12-18 months, which could drive valuation and partnership interest.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data readout for lead oncology candidate40% success
• Q1 2027IND filing for next-generation immunotherapy asset50% success
• 2026Strategic partnership or licensing deal for China/global rights30% success